PT1053019E - Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos - Google Patents

Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos

Info

Publication number
PT1053019E
PT1053019E PT99902172T PT99902172T PT1053019E PT 1053019 E PT1053019 E PT 1053019E PT 99902172 T PT99902172 T PT 99902172T PT 99902172 T PT99902172 T PT 99902172T PT 1053019 E PT1053019 E PT 1053019E
Authority
PT
Portugal
Prior art keywords
poly
glycol
ethylene
degradavas
acetylateral
Prior art date
Application number
PT99902172T
Other languages
English (en)
Inventor
J Milton Harris
Xuan Zhao
Original Assignee
Debio Rech Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debio Rech Pharma Sa filed Critical Debio Rech Pharma Sa
Publication of PT1053019E publication Critical patent/PT1053019E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
PT99902172T 1998-01-07 1999-01-06 Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos PT1053019E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7068098P 1998-01-07 1998-01-07

Publications (1)

Publication Number Publication Date
PT1053019E true PT1053019E (pt) 2004-04-30

Family

ID=22096751

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99902172T PT1053019E (pt) 1998-01-07 1999-01-06 Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos

Country Status (11)

Country Link
US (7) US6362276B1 (pt)
EP (1) EP1053019B1 (pt)
JP (1) JP3786832B2 (pt)
AT (1) ATE255422T1 (pt)
AU (1) AU755051B2 (pt)
CA (1) CA2316834C (pt)
DE (1) DE69913316T2 (pt)
DK (1) DK1053019T3 (pt)
ES (1) ES2211033T3 (pt)
PT (1) PT1053019E (pt)
WO (1) WO1999034833A1 (pt)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US8003705B2 (en) 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
WO1998012274A1 (en) 1996-09-23 1998-03-26 Chandrashekar Pathak Methods and devices for preparing protein concentrates
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US7642323B2 (en) 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
ATE255422T1 (de) * 1998-01-07 2003-12-15 Debio Rech Pharma Sa Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate
US7335220B2 (en) 2004-11-05 2008-02-26 Access Closure, Inc. Apparatus and methods for sealing a vascular puncture
GB2341185A (en) * 1998-09-07 2000-03-08 Polybiomed Ltd Polymerizable material and adhesive sheet material therefrom; dressings, electrodes and transdermal patches
AU6151799A (en) 1998-09-17 2000-04-03 Focal, Inc. Self-cleaning fluid delivery device for medical applications
DK1181323T3 (da) 1999-02-01 2011-10-17 Eidgenoess Tech Hochschule Biomaterialer dannet med nukleofil additionsreaktion med konjugerede uimættede grupper
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6828412B1 (en) * 1999-09-03 2004-12-07 School Of Pharmacy, University Of London Degradable polymers
US7037992B2 (en) * 1999-09-29 2006-05-02 Sri International Olefin copolymers containing hydrolytically cleavable linkages and use thereof in degradable products
US6288184B1 (en) * 1999-09-29 2001-09-11 Sri International Hydrolytically degradable olefin copolymers
WO2001026692A1 (en) * 1999-10-08 2001-04-19 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
WO2001046291A1 (en) 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
AU2001296962A1 (en) 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
JP4070605B2 (ja) 2000-10-19 2008-04-02 アイトゲノッシスシェ・テヒニッシュ・ホーホシューレ・ツューリヒ 多官能性自己集成系のためのブロックコポリマー
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) * 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
GB0116143D0 (en) * 2001-07-02 2001-08-22 Amersham Pharm Biotech Uk Ltd Chemical capture reagent
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
ES2516041T3 (es) 2001-10-10 2014-10-30 Ratiopharm Gmbh Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
EP2305311A3 (en) 2001-10-10 2011-07-20 BioGeneriX AG Glycoconjugation of peptides
PT2311432E (pt) 2002-06-07 2015-02-09 Dyax Corp Polipeptídeos de domínio kunitz modificado e sua utilização para a redução de isquemia ou aparecimento de uma resposta inflamatória sistémica associada a um procedimento cirúrgico
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7217254B2 (en) 2002-09-20 2007-05-15 Genzyme Corporation Multi-pressure biocompatible agent delivery device and method
RS20050300A (en) 2002-10-16 2007-08-03 Euro-Celtique S.A., Antibodies that bind cell-associated ca 125/0772p and methods of use thereof
US7311926B2 (en) * 2002-12-20 2007-12-25 Battelle Memorial Institute Biocomposite materials and methods for making the same
ES2420581T3 (es) 2003-03-14 2013-08-26 Biogenerix Gmbh Polímeros solubles en agua ramificados y sus conjugados
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2004103275A2 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7786213B2 (en) * 2003-10-15 2010-08-31 The Regents Of The University Of California Biomacromolecule polymer conjugates
CA2544223C (en) 2003-11-05 2017-03-07 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP1722834B1 (en) 2003-12-22 2012-06-27 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring crosslinked protein backbone
US7842667B2 (en) 2003-12-22 2010-11-30 Regentis Biomaterials Ltd. Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
JP5743368B2 (ja) 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー ペプチドのｏ結合型グリコシル化
US8470315B2 (en) 2004-04-13 2013-06-25 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
EP1609491B1 (en) 2004-06-16 2008-02-06 Straumann Holding AG Barrier membrane
US7282584B2 (en) 2004-06-16 2007-10-16 Straumann Holding Ag Methylene blue
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1625856A1 (en) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Hydrogel polymeric conjugates of a prodrug
EP2111872B1 (en) * 2004-07-05 2020-12-23 Ascendis Pharma GmbH Hydrogel conjugates
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
JP2008530305A (ja) 2005-02-09 2008-08-07 タイコ ヘルスケア グループ エルピー 合成封止剤
US20060222596A1 (en) 2005-04-01 2006-10-05 Trivascular, Inc. Non-degradable, low swelling, water soluble radiopaque hydrogel polymer
US7517914B2 (en) 2005-04-04 2009-04-14 Boston Scientificscimed, Inc. Controlled degradation materials for therapeutic agent delivery
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
WO2007008300A2 (en) 2005-05-31 2007-01-18 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Triblock copolymers for cytoplasmic delivery of gene-based drugs
WO2007007392A1 (ja) * 2005-07-11 2007-01-18 Wako Pure Chemical Industries, Ltd. 新規ポリマー及びこれを用いたコレステロール測定法
EP2412744B1 (en) 2005-07-18 2014-01-22 Nektar Therapeutics Method for preparing branched functionalised polymers using branched polyol cores
GB0515625D0 (en) * 2005-07-29 2005-09-07 Univ Manchester Hydrogel particle
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP2007112924A (ja) * 2005-10-21 2007-05-10 National Institute For Materials Science 高分子架橋剤及びこの架橋剤を用いたリポソーム又は細胞の架橋体
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP2023941B1 (en) 2006-04-24 2016-12-21 Incept, LLC Protein crosslinkers, crosslinking methods and applications thereof
US7872068B2 (en) 2006-05-30 2011-01-18 Incept Llc Materials formable in situ within a medical device
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
US8298801B2 (en) * 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008011165A2 (en) * 2006-07-21 2008-01-24 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
BRPI0719446A2 (pt) 2006-09-28 2013-12-10 Schering Corp Uso de il-10 peguilada para tratar câncer
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
SI2068907T1 (en) 2006-10-04 2018-01-31 Novo Nordisk A/S Pegylated sugars and glycopeptides are associated with glycerol
US8394483B2 (en) 2007-01-24 2013-03-12 Micron Technology, Inc. Two-dimensional arrays of holes with sub-lithographic diameters formed by block copolymer self-assembly
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US8083953B2 (en) 2007-03-06 2011-12-27 Micron Technology, Inc. Registered structure formation via the application of directed thermal energy to diblock copolymer films
US8557128B2 (en) 2007-03-22 2013-10-15 Micron Technology, Inc. Sub-10 nm line features via rapid graphoepitaxial self-assembly of amphiphilic monolayers
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
US8294139B2 (en) 2007-06-21 2012-10-23 Micron Technology, Inc. Multilayer antireflection coatings, structures and devices including the same and methods of making the same
US8097175B2 (en) 2008-10-28 2012-01-17 Micron Technology, Inc. Method for selectively permeating a self-assembled block copolymer, method for forming metal oxide structures, method for forming a metal oxide pattern, and method for patterning a semiconductor structure
US7959975B2 (en) 2007-04-18 2011-06-14 Micron Technology, Inc. Methods of patterning a substrate
US8372295B2 (en) 2007-04-20 2013-02-12 Micron Technology, Inc. Extensions of self-assembled structures to increased dimensions via a “bootstrap” self-templating method
US20080287633A1 (en) * 2007-05-18 2008-11-20 Drumheller Paul D Hydrogel Materials
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US8404124B2 (en) * 2007-06-12 2013-03-26 Micron Technology, Inc. Alternating self-assembling morphologies of diblock copolymers controlled by variations in surfaces
US8080615B2 (en) 2007-06-19 2011-12-20 Micron Technology, Inc. Crosslinkable graft polymer non-preferentially wetted by polystyrene and polyethylene oxide
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
EP2205271B1 (en) * 2007-10-08 2014-05-21 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
US8999492B2 (en) 2008-02-05 2015-04-07 Micron Technology, Inc. Method to produce nanometer-sized features with directed assembly of block copolymers
US8101261B2 (en) 2008-02-13 2012-01-24 Micron Technology, Inc. One-dimensional arrays of block copolymer cylinders and applications thereof
AU2009214615B2 (en) * 2008-02-13 2014-06-12 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
JP5150297B2 (ja) * 2008-02-14 2013-02-20 ネクター セラピューティックス エイエル，コーポレイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
US8426313B2 (en) 2008-03-21 2013-04-23 Micron Technology, Inc. Thermal anneal of block copolymer films with top interface constrained to wet both blocks with equal preference
US8425982B2 (en) 2008-03-21 2013-04-23 Micron Technology, Inc. Methods of improving long range order in self-assembly of block copolymer films with ionic liquids
US8114300B2 (en) 2008-04-21 2012-02-14 Micron Technology, Inc. Multi-layer method for formation of registered arrays of cylindrical pores in polymer films
US8114301B2 (en) 2008-05-02 2012-02-14 Micron Technology, Inc. Graphoepitaxial self-assembly of arrays of downward facing half-cylinders
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
JP5435536B2 (ja) * 2008-09-04 2014-03-05 学校法人神奈川大学 光分解性ブロックコポリマー
CN104961795A (zh) 2008-09-22 2015-10-07 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
EP2334695B1 (en) 2008-10-01 2015-12-23 Quintessence Biosciences, Inc. Therapeutic ribonucleases
WO2010068432A1 (en) 2008-11-25 2010-06-17 Ecole Polytechnique Federale De Lausanne (Epfl) Block copolymers and uses thereof
WO2010067378A2 (en) 2008-12-08 2010-06-17 Reliance Life Sciences Pvt. Ltd. Hydrogel composition
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
AU2010204648B2 (en) 2009-01-14 2016-09-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8409606B2 (en) 2009-02-12 2013-04-02 Incept, Llc Drug delivery through hydrogel plugs
EP2427233B1 (en) 2009-05-04 2016-12-21 Incept Llc Biomaterials for track and puncture closure
DK2440239T3 (en) 2009-06-09 2017-10-16 Prolong Pharmaceuticals Llc HEMOGLOBIN FORMATIONS
ES2636741T3 (es) 2009-07-31 2017-10-09 Sanofi-Aventis Deutschland Gmbh Composición de insulina de acción prolongada
MA33467B1 (fr) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Promédicaments comprenant un conjugué insuline-lieur
JP4704506B2 (ja) * 2009-08-11 2011-06-15 財団法人川村理化学研究所 有機無機複合ヒドロゲルおよびその製造方法
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20110081398A1 (en) * 2009-10-01 2011-04-07 Tyco Healthcare Group Lp Multi-mechanism surgical compositions
US8968785B2 (en) * 2009-10-02 2015-03-03 Covidien Lp Surgical compositions
US20110081701A1 (en) * 2009-10-02 2011-04-07 Timothy Sargeant Surgical compositions
JP5552310B2 (ja) * 2009-12-24 2014-07-16 日清紡ホールディングス株式会社 樹脂架橋剤
LT2521568T (lt) 2010-01-06 2018-12-10 Dyax Corp. Plazmos kalikreiną surišantys baltymai
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
US8304493B2 (en) 2010-08-20 2012-11-06 Micron Technology, Inc. Methods of forming block copolymers
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
JP2014502152A (ja) 2010-11-12 2014-01-30 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 癌の治療及び診断
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
WO2013059525A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US8900963B2 (en) 2011-11-02 2014-12-02 Micron Technology, Inc. Methods of forming semiconductor device structures, and related structures
EP2858661B1 (en) 2011-12-29 2020-04-22 Dana-Farber Cancer Institute, Inc. Stabilized antiviral fusion helices
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
CN108912211A (zh) 2012-02-15 2018-11-30 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
JP5953459B2 (ja) * 2012-03-27 2016-07-20 ネクター セラピューティクス ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
WO2014052647A2 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
US9087699B2 (en) 2012-10-05 2015-07-21 Micron Technology, Inc. Methods of forming an array of openings in a substrate, and related methods of forming a semiconductor device structure
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US10081654B2 (en) 2013-03-13 2018-09-25 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014151369A2 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
AU2014228777B2 (en) 2013-03-15 2018-11-08 Dana-Farber Cancer Institute, Inc. BH4 stabilized peptides and uses thereof
EP2970392B1 (en) 2013-03-15 2019-07-10 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US9229328B2 (en) 2013-05-02 2016-01-05 Micron Technology, Inc. Methods of forming semiconductor device structures, and related semiconductor device structures
WO2014201370A1 (en) 2013-06-14 2014-12-18 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
US9177795B2 (en) 2013-09-27 2015-11-03 Micron Technology, Inc. Methods of forming nanostructures including metal oxides
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
EP3143137A4 (en) 2014-05-14 2017-11-15 Trustees of Dartmouth College Deimmunized lysostaphin and methods of use
CN106573032B (zh) 2014-05-21 2022-03-18 哈佛大学的校长及成员们 Ras抑制肽和其用途
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
AU2016232833A1 (en) 2015-03-18 2017-10-12 Dana-Farber Cancer Institute, Inc. Selective Mcl-1 binding peptides
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3302547A1 (en) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2989311A1 (en) 2015-07-02 2017-01-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
WO2017035232A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2995479A1 (en) 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Peptides binding to bfl-1
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
JP6184462B2 (ja) * 2015-10-28 2017-08-23 ウェルズ ファーゴ バンク ナショナル アソシエイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
AU2016366557B2 (en) 2015-12-11 2024-01-25 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2017151617A1 (en) 2016-02-29 2017-09-08 Dana-Farber Cancer Institute, Inc. Stapled intracellular-targeting antimicrobial peptides to treat infection
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
AU2017315447B2 (en) 2016-08-26 2023-04-27 Dana-Farber Cancer Institute, Inc. Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
WO2018170299A1 (en) 2017-03-15 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of prokaryotic gene transcription and uses thereof
JP6361083B2 (ja) * 2017-06-27 2018-07-25 ウェルズ ファーゴ バンク ナショナル アソシエイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
JP7305614B2 (ja) 2017-07-19 2023-07-10 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド
US11847932B2 (en) 2017-09-07 2023-12-19 Intuitive Surgical Operations, Inc. Modified animal organs for use in surgical simulators
JP2021506814A (ja) 2017-12-15 2021-02-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化ペプチドによって介在される標的タンパク質の分解
AU2018383633B2 (en) 2017-12-15 2024-05-16 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
EP3749678A1 (en) 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
US20200408746A1 (en) 2018-03-14 2020-12-31 Dana-Farber Cancer Institute, Inc. Stabilized Peptides for Biomarker Detection
JP6500318B2 (ja) * 2018-04-04 2019-04-17 ウェルズ ファーゴ バンク ナショナル アソシエイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
US11286299B2 (en) 2018-09-17 2022-03-29 Massachusetts Institute Of Technology Peptides selective for Bcl-2 family proteins
JP2022530853A (ja) 2019-04-18 2022-07-04 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 構造的に安定化されたペプチドによるユビキチンおよびユビキチン様ｅ１活性化酵素の選択的標的化
CN110668933A (zh) * 2019-09-30 2020-01-10 兰州交通大学 一种合成烯丙基脂肪醇聚氧乙烯醚羧酸（apea-7）的新方法
CN110759824A (zh) * 2019-09-30 2020-02-07 兰州交通大学 一种合成烯丙基脂肪醇聚氧乙烯醚羧酸（apea-3）的新方法
US20230116760A1 (en) 2019-12-16 2023-04-13 Dana-Farber Cancer Institute, Inc. Structurally-stabilized oncolytic peptides and uses thereof
WO2021127493A1 (en) 2019-12-20 2021-06-24 Dana-Farber Cancer Institute, Inc. Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
AU2021230544A1 (en) 2020-03-04 2022-09-01 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized SARS-CoV-2 peptides and uses thereof
AU2021258205A1 (en) 2020-04-22 2022-10-13 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ACE2 helix 1 peptides and uses thereof
WO2021222243A2 (en) 2020-04-27 2021-11-04 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
US20230330238A1 (en) 2020-10-14 2023-10-19 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
EP4240395A1 (en) 2020-11-05 2023-09-13 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ebolavirus peptides and uses thereof
IL311151A (en) 2021-09-08 2024-04-01 Dana Farber Cancer Inst Inc Structurally clamped antiviral SARS-COV-2 peptide-cholesterol conjugates and uses thereof
WO2023215784A1 (en) 2022-05-04 2023-11-09 Dana-Farber Cancer Institute, Inc. Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419006A (en) 1966-08-08 1968-12-31 Union Carbide Corp Novel dressing and use thereof
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3963805A (en) 1974-10-30 1976-06-15 Union Carbide Corporation Water swellable poly(alkylene oxide)
ATE14979T1 (de) 1979-03-21 1985-09-15 Nat Res Dev Zusammensetzung mit geregelter wirkstofffreigabe und verfahren zu ihrer herstellung.
JPS585320A (ja) 1981-07-01 1983-01-12 Toray Ind Inc グラフト共重合体
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5626863A (en) 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5334640A (en) * 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
WO1993024476A1 (en) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
DE4342154A1 (de) 1993-12-10 1995-06-14 Behringwerke Ag Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
WO1996020012A2 (en) 1994-12-23 1996-07-04 Middlesex Sciences, Inc. Methods for preparing and purifying macromolecular conjugates
ATE342295T1 (de) 1995-07-28 2006-11-15 Genzyme Corp Biologische abbaubare multiblokhydrogene und ihre verwendung wie trägerstoffe fur kontrollierte freisetzung pharmakologisch activen werstoffe und gewebekontaktmaterialen
CN1137911C (zh) * 1995-08-23 2004-02-11 三井化学株式会社 新颖的烯丙醚、烯丙醚聚合物和聚合物固体电解质
ZA978537B (en) * 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
ZA987019B (en) 1997-08-06 1999-06-04 Focal Inc Hemostatic tissue sealants
US6316522B1 (en) * 1997-08-18 2001-11-13 Scimed Life Systems, Inc. Bioresorbable hydrogel compositions for implantable prostheses
US6448369B1 (en) * 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
ATE255422T1 (de) * 1998-01-07 2003-12-15 Debio Rech Pharma Sa Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate
US6326276B1 (en) * 1999-08-10 2001-12-04 United Microelectronics Corp. Method for forming a capacitor in dram

Also Published As

Publication number Publication date
US7214388B2 (en) 2007-05-08
EP1053019B1 (en) 2003-12-03
AU755051B2 (en) 2002-12-05
DE69913316T2 (de) 2004-11-18
AU2221499A (en) 1999-07-26
US20010016624A1 (en) 2001-08-23
US20040086992A1 (en) 2004-05-06
US20120195846A1 (en) 2012-08-02
DK1053019T3 (da) 2004-04-13
ES2211033T3 (es) 2004-07-01
EP1053019A1 (en) 2000-11-22
WO1999034833A1 (en) 1999-07-15
US6362276B1 (en) 2002-03-26
WO1999034833A9 (en) 2005-03-17
US20070292931A1 (en) 2007-12-20
JP3786832B2 (ja) 2006-06-14
US7166304B2 (en) 2007-01-23
ATE255422T1 (de) 2003-12-15
CA2316834A1 (en) 1999-07-15
DE69913316D1 (de) 2004-01-15
US8497357B2 (en) 2013-07-30
US20040086991A1 (en) 2004-05-06
CA2316834C (en) 2006-01-03
JP2003510375A (ja) 2003-03-18
US20110009589A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
PT1053019E (pt) Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos
DK1028753T3 (da) Indgivelse af poly(ethylenglycol)-konjugerede molekyler fra nedbrydellige hydrogeler
CA2323048A1 (en) Poly(ethylene glycol) derivatives with proximal reactive groups
ES2121180T3 (es) Sintesis mejorada de conjugados de polimero/sustancia bioactiva.
DE69800640T2 (de) Pegylationsverfahren
TR200200843T2 (tr) İşemi'nin Tedavisi için olan bileşikler
CA2268433A1 (en) Improved interferon polymer conjugates
CA2301533A1 (en) Balloons made from liquid crystal polymer blends
BR9610695A (pt) Polipeptideo conjugado em um polipeptídeo e um polímero biocompatível e do fator viii do fator de von willebrand ou um combinação destes e utilização dos mesmos
TR200101867T2 (tr) CCR5 modülatörleri olarak piperidinler
ATE356638T1 (de) Hydrolytisch abbaubare carbamatderivate von polyethylenglykol
EP1300139A3 (de) Arzneistoffträgerpartikel für die gewebspezifische Arzneistoffapplikation
ATE257014T1 (de) Lichtbilderzeugungskontrastmitteln
WO2002085419A3 (en) Bifunctional-modified hydrogels
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
NO952077D0 (no) Sammensetning bestående av en dendrimer og en aktiv substans okkludert deri
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
NO20011860L (no) Polymerkonjugater av interferon <beta>-1A samt anvendelse derav
WO2003037384A3 (en) Polymer conjugates of protein kinase c inhibitors
FR2752843B1 (fr) Copolymeres reticules a base de polymeres polycarboxyliques et leur utilisation comme support de composition pharmaceutique
EA199900428A1 (ru) Конъюгаты, используемые в лечении рака предстательной железы
WO2001094547A3 (en) Molecular delivery vehicle for delivery of selected compounds to targets
DE10084671T1 (de) Pharmazeutische Zusammensetzungen
CA2324467A1 (en) Formulations for protection of peg-interferon alpha conjugates
BR9815530A (pt) Quimioterapia sìtio-dirigida de metástases